Denufosol

Drug Profile

Denufosol

Alternative Names: Denufosol tetrasodium; INS 37217; INS 37217 ophthalmic; INS37217 Respiratory

Latest Information Update: 18 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inspire Pharmaceuticals
  • Class Decongestants; Expectorants; Eye disorder therapies; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis

Highest Development Phases

  • Discontinued Cystic fibrosis; Dry eyes; Perennial allergic rhinitis; Retinal disorders; Retinal oedema; Sinusitis

Most Recent Events

  • 18 Feb 2011 Discontinued - Phase-II for Cystic fibrosis in USA (Inhalation)
  • 18 Feb 2011 Discontinued - Phase-III for Cystic fibrosis in Australia (Inhalation)
  • 18 Feb 2011 Discontinued - Phase-III for Cystic fibrosis in Canada (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top